Dawn L. Wydner

Quality & Compliance Practice

BACKGROUND

FOCUS AREAS

AWARDS & HONORS

10-year global quality and compliance career in the FDA’s Office of Regulatory
Affairs andover 20 years global quality and compliance direction for pharmaceutical, medical device, and consumer R&D functions.

GCP, GLP, GMP processes, including post market surveillance
Audits and compliance, safety, and quality monitoring
Operational strategy and risk management across all GxPs

FDA Commendation Medal
Conduct of Sterile Medical Device Manufacturer inspection resulting in Injunction and Warning Letter
Performance of GCP Sponsor Monitor Inspection leading to Warning Letter of Large Pharmaceutical
Conduct of GCP inspection resulting in Warning Letter of Contract Research Organization
Completion of GLP inspection resulting in Untitled Letter

FDA Exemplary Performance Award for Leadership and guidance in FDAs International Regulatory Collaboration Initiative

Dawn Wydner joined ELIQUENT, formally Greenleaf Health, as Senior Vice President, Regulatory Compliance, after working closely with Greenleaf’s Quality, Manufacturing, and Compliance Team as an independent consultant. Dawn has extensive FDA regulatory compliance expertise as well as quality and compliance experience within industry. During her ten years at the U.S. Food and Drug Administration (FDA), she was a Commissioned Public Health Service Medical Officer, conducting complex, thorough bioresearch monitoring (BIMO) inspections to assess good clinical practices (GCPs), good laboratory practices (GLPs), and good manufacturing practices (GMPs) under medical device and drug compliance programs domestically and internationally. She has also worked in bioresearch quality and compliance and clinical quality assurance roles for Janssen Research & Development, where she managed company-wide, global compliance activities and provided expert strategic direction and advice to senior leadership.

Dawn offers ELIQUENT clients a deep understanding of all aspects of operational strategy, coordination, and conduct to ensure quality, safety, and compliance across the global pharmaceutical R&D, medical device, and consumer products industries. Her expertise covers the end-to-end lifecycle of a product and processes from GLP to GCP to GMP, including post marketing surveillance; audits and compliance, safety, and quality monitoring; and operational risk management across all GxPs. She is frequently sought as a subject matter expert based on her proven track record of consistently establishing proactive compliance and application of quality oversight. Dawn is adept at utilizing her broad skillset to enable easy collaboration, big-picture strategic thinking, and compliance mindsets.

Prior to her career at the FDA, Dawn worked as a Registered Nurse in the hospital setting, caring for patients within transitional trauma, pediatrics, infectious diseases, and oncology. She has obtained her Ph.D. in Health Psychology and RQAP-GCP certification.

Ready for Regulatory Clarity?

Stay informed as the regulatory landscape evolves. 

Subscribe to our blog to receive the latest updates on policy changes, FDA developments, and their impact on the life sciences industry.